AB060. SOH21AS258. The prognostic value of metabolomics with genomic single nucleotide polymorphism cross-talk for colorectal cancer recurrence and 5-year overall survival

Christina Fleming¹, Helen Mohan², Donal Peter O’Leary³, Jennifer Kirwan⁴, Henry Redmond¹

¹Department of Academic Surgery, Cork University Hospital, Cork, Ireland; ²Department of Colorectal Surgery, St. Vincents University Hospital, Dublin, Ireland; ³Department of Surgical Oncology, Bons Secours Hospital Cork, Cork, Ireland; ⁴Metabolomics Facility, BIH, Max Delbrüch Centre for Molecular Medicine, Berlin Institute of Health, Berlin, Germany

Background: Metabolomic analysis in colorectal cancer (CRC) is an emerging research area. We aimed to examine current evidence and identify prognostic metabolomic signatures for CRC recurrence and overall survival and cross-reference this data with prognostic genomic single nucleotide polymorphisms (SNPs).

Methods: A systematic review of studies utilising metabolomics to identify patients at risk of cancer recurrence and poor survival outcomes in CRC was performed in keeping with PRISMA guidelines. The QUADOMICS tool was used to assess study quality. MetaboAnalyst software, version 4.0 was used to perform metabolic pathway enrichment and identify genomic SNPs associated with CRC prognosis, referencing the following databases: Human Metabolome Database (HMDB), the Small Molecule Pathway Database (SMPDB), PubChem and Kyoto Encyclopaedia of Genes and Genomes (KEGG) Pathway Database. Cohort validation was performed in an Irish population.

Results: Nine studies met the inclusion criteria, reporting on 1,117 patients. Increased metabolic activity in the urea cycle (P=0.002, FDR-0.198) ammonia recycling (P=0.004, FDR=0.359) and glycine and serine metabolism (P=0.004, FDR=0.374) were prognostic of CRC recurrence. Increased activity in aspartate metabolism (P=8.13E-04, FDR=0.079) and ammonia recycling (P=0.004, FDR=0.345) were prognostic of survival. Eight resulting SNPs were prognostic for CRC recurrence (Rs2194980, Rs1392880, Rs2567397, Rs715, Rs169712, Rs2300701, Rs313408, Rs7018169) and three for survival (Rs2194980, Rs169712, Rs12106698) of which two overlapped with recurrence (Rs2194980, Rs169712). Poor prognostic metabolomes were further identified on cohort validation, in particular in patients with high visceral fat and/or sarcopenia.

Conclusions: Specific metabolites and metabolic pathways are dysregulated in the setting of poor prognostic CRCs and such metabolic signatures are associated with specific genomic SNPs. These findings provide a platform for prognostic biomarker discovery and development in CRC as well as identify potential for therapeutic targeting.

Keywords: Metabolomics; omics; colon cancer; biomarkers

Acknowledgments

Funding: This work was supported by a research fellowship funded by the European Association for Cancer Research.

Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/map-21-ab060). DPO serves as an unpaid editorial board member of Mesentery and Peritoneum. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-21-ab060